BAA2D0D4-DD8C-4F80-8D37-986AFC578536
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 20.59789750328515
- age_years
- 31
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.404
- NOTCH_SIGNALING+0.402
- PROTEIN_SECRETION+0.399
- MITOTIC_SPINDLE+0.343
- ANDROGEN_RESPONSE+0.295
- CHOLESTEROL_HOMEOSTASIS+0.288
- WNT_BETA_CATENIN_SIGNALING+0.284
- OXIDATIVE_PHOSPHORYLATION+0.267
- UV_RESPONSE_DN+0.247
- MYC_TARGETS_V2+0.226
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.493
- COAGULATION-0.433
- IL6_JAK_STAT3_SIGNALING-0.423
- INTERFERON_GAMMA_RESPONSE-0.414
- INFLAMMATORY_RESPONSE-0.367
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- TNFA_SIGNALING_VIA_NFKB-0.347
- COMPLEMENT-0.346
- INTERFERON_ALPHA_RESPONSE-0.336
- ANGIOGENESIS-0.334
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | EF7D394C-BAB6-4826-AE09-9E5E884E0023 | — | — | 0.950 |
| 2 | 713B4DA5-FA8A-4E52-BACF-19B912467FBB | — | — | 0.929 |
| 3 | 9E2420C3-FD2A-45BB-B5A3-DC25D9F7CB3C | — | — | 0.925 |
| 4 | D47BE4CF-FF4F-4422-89AE-9AFAE192309C | — | — | 0.906 |
| 5 | DE406E2B-39AF-4A24-B2BE-0F7CDCBE9D85 | — | — | 0.903 |
| 6 | E3818BAA-BA28-4CE4-A745-BB3692883888 | — | — | 0.899 |
| 7 | 9F204EEA-9026-4367-8586-C2127D55AC5E | — | — | 0.894 |
| 8 | A770E81F-8898-4632-A839-7950EED7CF7A | — | — | 0.888 |
| 9 | 2C70D7BF-85C4-447B-B0F9-A129D6B49E77 | — | — | 0.886 |
| 10 | SRR934798 | — | — | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.404 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.402 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.399 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.343 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.295 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.288 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.284 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.267 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.247 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.226 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.198 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.192 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.181 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.157 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.147 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.143 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.114 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.106 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.106 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.103 | Temsirolimus | — uncovered |